Clinical Pharmacists Participating in Drug Analysis and Adjustment for a Patient with Drug-induced Liver Injury

Abstract

Abstract: ObjectiveTo provide reference for nephrology clinical pharmacist participating in the therapy for a patient with drug-induced liver injury. MethodsClinical pharmacists participated in analysis and adjustment of therapeutic scheme for a patient with drug-induced liver injury. In consideration of the characteristics of the patient,such as the age, nephrotic syndrome with hypokalemia and miliary tuberculosis, it is suggested that physician discontinued the suspicious drugs and adjusted the liver protective drugs. ResultsTaking the characteristics of the patient into consideration, clinical pharmacists assisted physician actively to provide reasonable drug therapy scheme for patient from drug interaction and adverse reaction. The liver function of the patient recovered after treatment. ConclusionClinical pharmacist in nephrology department participating in clinical practice can play advantages from the perspective of pharmacy to optimize therapeutic scheme.

Key words: clinical pharmacist, drug analysis, nephrology department, drug-induced liver injury

CLC Number:

R969.3

HUANG Hai-hua, DENG Ang, KONG Xu-dong, TANG Kun. Clinical Pharmacists Participating in Drug Analysis and Adjustment for a Patient with Drug-induced Liver Injury[J]. Chinese Journal of Pharmacovigilance, 2014, 11(8): 501-503.

References

[1] Liu z x, Govindarajan S, Kaplowitz N.Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity[J].Gastroenterology, 2004, 127(6) : 1760-1774.
[2] 郭英江,崔得健.抗结核药所致肝损害[J].中华结核和呼吸杂志,1998,21(5)：308-309.
[3] 纪福生,解林静.嗜酒结核病患者用异烟肼、利福喷丁和吡嗪酰胺治疗出现严重肝损害[J].药物不良反应杂志,2008,10(2)：145-146.
[4] 王兰霞,强生萍.莫西沙星致肝功能异常1例[J].中国药物警戒,2012,9(7) :445.
[5] 茅益民,刘晓琳,陈成伟. 2013年美国FDA药物性肝损伤指南介绍-医药研发企业上市前的临床评估[J].肝脏,2013,18（5）:325-330.
[6] 邓万俊.他汀类药物与其他药物的相互作用[J].中国新药与临床杂志,2006,25（2）：131-136.
[7] 张清,赵英明,陈波,等.他汀对既往有乙肝病毒感染史患者肝损害的影响[J].中国介入心脏病学杂志,2011,19 (4) : 223-226.
[8] 邓华,雷招宝. 他汀类药物引起的肝损害[J].药物不良反应杂志,2012,14(2)：88-92.
[9] 章利芬. 瑞舒伐他汀钙片致药物性肝炎1例报告[J]. 海峡药学杂志,2012,24(12): 289.
[10] Wagayama H,Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone[J].J Hepatol, 2000, 32(5): 874.
[11] Arai M, Yokosuka O, Fujiwara K,et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report[J].J Gastr-oenterol Hepatol, 2002, 17(5): 625-626.
[12] 胡晓娜,保志军. 药物性肝损害的流行病学[J].中华肝脏病杂志,2011,19(1):78-80.
[13] Lee B H, Koh W J, Choi M S, et al. Inactive hepatitis B surface antigen carrier state and heaptotoxicity during antituberculosis chemotherapy[J]. Chest, 2005, 127(4): 1304-1311.
[14] 陈瑜. 血液病患者药物性肝损伤的预防和规范化治疗专家共识[J].中华血液学杂志,2012,33（3）:252-256.
[15] 孙琪. 抗结核药所致肝损伤之中医治疗进展[J].世界中西医结合杂志,2009,4(11):835-836.